Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;23(6-b Suppl):S2-S8.
doi: 10.18553/jmcp.2017.23.6-b.s2.

The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis

Neal Hermanowicz  1 , Gustavo Alva  2 , Fernando Pagan  3 , Alberto J Espay  4 , Amita Patel  5 , Katya Cruz Madrid  6 , Daniel Kremens  7 , Jim Kenney  8 , Sheila Arquette  9 , Gary Tereso  10 , Maria Lopes  11 , Carolyn Farnum  11
Affiliations
Review

The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis

Neal Hermanowicz et al. J Manag Care Spec Pharm. 2017 Jun.

Abstract

A panel of experts drawn from neurology, psychiatry, geropsychiatry, geriatrics, and pharmacy representatives of 3 health plans convened in New York City on July 30, 2016, with the objective of sharing opinions, ideas, and information regarding the optimal management of Parkinson's disease psychosis (PDP). Three key points emerged from the discussion: (1) Because of the nature of Parkinson's disease and PDP, finding appropriate treatment can prove challenging; (2) emerging therapies may present an opportunity for effective disease management; and (3) moving forward, provider and patient education regarding PDP and available treatment options is essential for well-managed symptoms and better quality of life. The panel reviewed current practices and formulated recommendations on moving forward in the treatment of PDP.

Disclosures: This project and manuscript was funded by ACADIA Pharmaceuticals and developed by Magellan Rx Management. Lopes and Farnum are employees of Magellan Rx Management. Kremens has received consulting/speaker fees from Teva Pharmaceuticals, UCB, Sunovion, Impax, Lundbeck, ACADIA, USWorldMeds, Merz, Acorda, Kyowa, Neurocrine, and GE Healthcare. Pagan reports consulting/speaker fees from Teva Nanoscience, AbbVie, Impax, ACADIA, Medtronic, USWorldMeds, Merz, and Cynapsus and research and educational grants from USWorldMeds, Teva, and Medtronic. Patel has received consultant/speaker fees from ACADIA, Allergen, and Avanir. Alva reports research support from Accera, Allergan, Axovant, Eisai, Neurotrope, Genentech, Intra Cellular, Janssen, Lundbeck, Neurim, Novartis, Otsuka, Roche, Suven, and Trans Tech and consultant/speaker fees from ACADIA, Alkermes, Allergan, Avanir, Janssen, Lundbeck, Merck, Nestle, Otsuka, Sunovion, Takeda, and Vanda. The other authors report no potential conflicts of interest, financial or otherwise.

PubMed Disclaimer

Conflict of interest statement

This project and manuscript was funded by ACADIA Pharmaceuticals and developed by Magellan Rx Management. Lopes and Farnum are employees of Magellan Rx Management. Kremens has received consulting/speaker fees from Teva Pharmaceuticals, UCB, Sunovion, Impax, Lundbeck, ACADIA, USWorldMeds, Merz, Acorda, Kyowa, Neurocrine, and GE Healthcare. Pagan reports consulting/speaker fees from Teva Nanoscience, AbbVie, Impax, ACADIA, Medtronic, USWorldMeds, Merz, and Cynapsus and research and educational grants from USWorldMeds, Teva, and Medtronic. Patel has received consultant/speaker fees from ACADIA, Allergen, and Avanir. Alva reports research support from Accera, Allergan, Axovant, Eisai, Neurotrope, Genentech, Intra Cellular, Janssen, Lundbeck, Neurim, Novartis, Otsuka, Roche, Suven, and Trans Tech and consultant/speaker fees from ACADIA, Alkermes, Allergan, Avanir, Janssen, Lundbeck, Merck, Nestle, Otsuka, Sunovion, Takeda, and Vanda. The other authors report no potential conflicts of interest, financial or otherwise.

Figures

FIGURE 1
FIGURE 1
Primary Endpoint SAPS-PD Score (mITT, MMRM, N = 185)
See this image and copyright information in PMC

References

    1. Dorsey ER, Constantinescu R, Thompson JP, et al. . Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384-86. - PubMed
    1. Olanow CW, Schapira AHV.. Parkinson’s disease and other movement disorders. In: Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J, eds.. Harrison’s Principles of Internal Medicine. 18th ed. Vols. 1 and 2. New York: McGraw-Hill; 2012:3317-34.
    1. Ravina B, Marder K, Fernandez HH, et al. . Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22(8):1061-68. - PubMed
    1. Hermanowicz N, Edwards K.. Parkinson’s disease psychosis: symptoms, management, and economic burden. Am J Manag Care. 2015;21(10 Suppl):s199-206. - PubMed
    1. Klein C, Prokhorov T, Miniovitz A, Dobronevsky E, Rabey JM.. Admission of Parkinsonian patients to a neurological ward in a community hospital. J Neural Transm (Vienna). 2009;116(11):1509-12. - PubMed

LinkOut - more resources